TITLE

Impact of Chronic Hepatitis B Virus (HBV) Infection on Outcomes of Patients Infected with HIV in an Area Where HBV Infection Is Hyperendemic

AUTHOR(S)
Sheng, Wang-Huei; Chen, Mao-Yuan; Hsieh, Szu-Min; Hsiao, Chin-Fu; Wang, Jann-Tay; Hung, Chien-Ching; Chang, Shan-Chwen
PUB. DATE
May 2004
SOURCE
Clinical Infectious Diseases;5/15/2004, Vol. 38 Issue 10, p1471
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Between June 1994 and February 2003, a total of 111 human immunodeficiency virus (HIV)-infected patients with chronic hepatitis B virus (HBV) coinfection and 387 HIV-infected patients without HBV or hepatitis C virus coinfection were prospectively observed to assess the impact of HBV infection on outcomes of HIV- infected patients. After a median duration of observation of 25 months, coinfected patients were more likely to develop hepatitis (adjusted hazard ratio [AHR], 2.54; 95% confidence interval [CI], 1.69-3.82) and hepatic decompensation (adjusted odds ratio [AOR], 9.94; 95% CI, 1.89-52.35). Although similar proportions of the 2 patient groups had an increase in the CD4 count by ⩾100× 106 cells/L (AOR, 0.78; 95% CI, 0.45-1.36) and development of new opportunistic illnesses (AOR, 0.94; 95% CI, 0.53-1.66), HBV-infected patients had an increased risk for virologic failure (AOR, 1.76; 95% CI, 1.03-2.99) and death (AHR, 1.71; 95% CI, 1.19-2.47) after highly active antiretroviral therapy was initiated.
ACCESSION #
13077171

 

Related Articles

  • Infection Control in Jails and Prisons. Bick, Joseph A. // Clinical Infectious Diseases;10/15/2007, Vol. 45 Issue 8, p1047 

    At the end of 2005, ∼7 million people (or 1 of every 33 American adults) were either in jail, in prison, or on parole [1]. Compared with the general public, newly incarcerated inmates have an increased prevalence of human immunodeficiency virus infection, hepatitis B virus infection,...

  • Drugs to Treat Both HIV, Hepatitis C.  // Guide;Apr2004, Vol. 24 Issue 4, p19 

    Reports that Roche Corp. said a trial of a two-drug combination therapy for HIV-positive persons with hepatitis C virus showed a marked benefit against viral levels. Hepatitis C drug Pegasys and antiviral Copegus; Sustained 40 percent virological response in a trial of 868 patients; Virological...

  • Viral Hepatitis in HIV Infection. Koziel, Margaret James; Peters, Marion G. // New England Journal of Medicine;4/5/2007, Vol. 356 Issue 14, p1445 

    The article discusses the occurrence of hepatitis C virus and hepatitis B virus infections in patients with HIV infection. The infections share routes of viral transmission. It is recommended that patients with HIV infection receive a vaccination against hepatitis A virus and hepatitis B virus....

  • The study of hepatitis B surface antigen and anti- HCV in HIV infected patients. Girish, N.; Nagarathnamma, T.; Saileela, K.; Sreekanth, B.; Venkatesha, D. // BMC Infectious Diseases;2012 Supplement, Vol. 12 Issue Supplment 1, p1 

    The article discusses a study on the co-infection of hepatitis B virus (HBV) and hepatitis C virus (HCV) in HIV infected patients and the diseases' mode of transmission. The study tests the sera of 106 HIV positive patients with history of heterosexual contact and 30 asymptomatic healthy...

  • Hepatitis B Virus Drug Resistance in HIV-1–Infected Patients Taking Lamivudine-Containing Antiretroviral Therapy. Wongprasit, Pawinee; Manosuthi, Weerawat; Kiertiburanakul, Sasisopin; Sungkanuparph, Somnuek // AIDS Patient Care & STDs;Apr2010, Vol. 24 Issue 4, p205 

    A cross-sectional study was conducted in HIV-1–infected patients receiving lamivudine-containing antiretroviral therapy (ART) to determine the prevalence and risk factors of hepatitis B virus drug resistance (HBV-DR). HBV DNA and HBV genotypic resistance test were performed. Patients were...

  • SHEA guideline for management of healthcare workers who are infected with Hepatitis B virus, Hepatitis C virus, and/or Human Immunodeficiency Virus.  // British Dental Journal;4/10/2010, Vol. 208 Issue 7, p303 

    '...HIV infected provider who has a viral burden of less than 5 × 102 GE/mL not be excluded from any aspect of patient care'.

  • Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010. Moon Jung Kim; Quehn Park; Hyuk Ki Min; Hyun Ok Kim // BMC Infectious Diseases;2012, Vol. 12 Issue 1, p160 

    Background: Despite screening blood donations with advanced technologies and improved donor screening, the risk of transfusion-transmitted infections persists. This risk is mainly due to blood donations collected during the window period. A precise estimate of the transfusion risk of viral...

  • Forgiveness of non-adherence to HIV-1 antiretroviral therapy.  // Journal of Antimicrobial Chemotherapy (JAC);Apr2008, Vol. 61 Issue 4, p769 

    Superior adherence to HIV-1 antiretroviral therapy is a mainstay of successful HIV management. Studies performed in the early era of highly active antiretroviral therapy demonstrated the need for ≥95% adherence in order to achieve and sustain viral suppression. High rates of viral...

  • Therapeutic Interventions for HIV Infection and Chronic Viral Hepatitis. Cooper, Curtis L. // Clinical Infectious Diseases;7/1/2005 Supplement, Vol. 41, pS69 

    Combination antiretroviral therapy reduces overall and liver-specific morbidity and mortality in coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) and represents the most beneficial pharmaceutical treatment intervention for most coinfected patients. Antiviral...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics